-
Kelley RK, Venook AP. Nonadherence to Imatinib during an
Economic Downturn. N Engl J Med. 2010 Aug 5; 363(6):596-8.
-
Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y,
Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J,
Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma:
consensus recommendations of the national cancer institute clinical
trials planning meeting. J Clin Oncol. 2010 Sep 1;
28(25):3994-4005.
-
Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular
carcinoma: Ablate and wait versus rapid transplantation. Liver
Transpl. 2010 Aug; 16(8):925-9.
-
Lencioni R, Marrero J, Venook A, Ye SL, Kudo M. Design and
rationale for the non-interventional Global Investigation of
therapeutic DEcisions in hepatocellular carcinoma and Of its
treatment with sorafeNib (GIDEON) study. Int J Clin Pract. 2010
Jul; 64(8):1034-41.
-
Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R,
Venook AP. Nonoperative therapies for combined modality treatment
of hepatocellular cancer: expert consensus statement. HPB (Oxford).
2010 Jun; 12(5):313-20.
-
Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P,
Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, Saltz LB.
Phase II Study of the Anti-Cytotoxic T-Lymphocyte-Associated
Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With
Refractory Metastatic Colorectal Cancer. J Clin Oncol. 2010 Jul 20;
28(21):3485-90.
-
Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren
RS, Nakakura EK. Identification of unknown primary tumors in
patients with neuroendocrine liver metastases. Arch Surg. 2010 Mar;
145(3):276-80.
-
Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E,
Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of
bevacizumab plus erlotinib for gemcitabine-refractory metastatic
pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov;
66(6):1051-7.
-
Engstrom PF, Arnoletti JP, Benson AB, Berlin JD, Berry JM,
Chen YJ, Choti MA, Cooper HS, Dilawari RA, Early DS, Enzinger PC,
Fakih MG, Fleshman J, Fuchs C, Grem JL, Knol JA, Leong LA, Lin E,
Mulcahy MF, Rohren E, Ryan DP, Saltz L, Shibata D, Skibber JM,
Small W, Sofocleous C, Thomas J, Venook AP, Willett C. NCCN
Clinical Practice Guidelines in Oncology: Anal Carcinoma. J Natl
Compr Canc Netw. 2010 Jan; 8(1):106-20.
-
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA,
Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG,
Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E,
Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM,
Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical
Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc
Netw. 2009 Sep; 7(8):778-831.
-
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA,
Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG,
Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E,
Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM,
Sofocleous C, Thomas J, Venook AP, Willett C. NCCN Clinical
Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc
Netw. 2009 Sep; 7(8):838-81.
-
Kelley R, Venook AP. Drug development in advanced colorectal
cancer: challenges and opportunities. Curr Oncol Rep. 2009 May;
11(3):175-85.
-
Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF,
Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger
WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill
SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous
C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical
practice guidelines in oncology: hepatobiliary cancers. J Natl
Compr Canc Netw. 2009 Apr; 7(4):350-91.
-
Shah U, O'Neil B, Allen J, Goldberg RM, Bernard S, Moore D,
Venook AP, Morse MM. A Phase II Study of Long-Acting Octreotide in
Patients With Advanced Hepatocellular Carcinoma and CLIP Score of 3
or Higher. Gastrointest Cancer Res. 2009 Mar; 3(2):45-8.
-
Fan SK, Venook AP, Lu Y. Design issues in dose-finding Phase I
trials for combinations of two agents. J Biopharm Stat. 2009;
19(3):509-23.